Resection of hepatocellular cancer ≤2 cm: Results from two Western centers

Authors

  • Sasan Roayaie,

    Corresponding author
    1. Liver Cancer Program, Mount Sinai Medical Center, New York, NY
    • Sasan Roayaie, Department of Surgery, Mount Sinai Medical Center, One Gustave L. Levy Place, Box 1259, New York, NY 10029===

      Vincenzo Mazzaferro, Department of Surgery, Istituto Nazionale Tumori, Via Venezian 1, Milan, Italy 20133===

    Search for more papers by this author
    • fax: 212-241-1572

  • Khaled Obeidat,

    1. Liver Cancer Program, Mount Sinai Medical Center, New York, NY
    Search for more papers by this author
  • Carlo Sposito,

    1. Hepato-Oncology Group, Surgery, Gastroenterology, Pathology, and Biostatistics, National Cancer Institute—Istituto Nazionale dei Tumori, Milan, Italy
    Search for more papers by this author
  • Luigi Mariani,

    1. Hepato-Oncology Group, Surgery, Gastroenterology, Pathology, and Biostatistics, National Cancer Institute—Istituto Nazionale dei Tumori, Milan, Italy
    Search for more papers by this author
  • Sherrie Bhoori,

    1. Hepato-Oncology Group, Surgery, Gastroenterology, Pathology, and Biostatistics, National Cancer Institute—Istituto Nazionale dei Tumori, Milan, Italy
    Search for more papers by this author
  • Alessandro Pellegrinelli,

    1. Hepato-Oncology Group, Surgery, Gastroenterology, Pathology, and Biostatistics, National Cancer Institute—Istituto Nazionale dei Tumori, Milan, Italy
    Search for more papers by this author
  • Daniel Labow,

    1. Liver Cancer Program, Mount Sinai Medical Center, New York, NY
    Search for more papers by this author
  • Josep M. Llovet,

    1. Liver Cancer Program, Mount Sinai Medical Center, New York, NY
    2. Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clínic of Barcelona, Barcelona, Catalonia, Spain
    3. Institució Catalana d'Estudis Avancats, Barcelona, Catalonia, Spain
    Search for more papers by this author
  • Myron Schwartz,

    1. Liver Cancer Program, Mount Sinai Medical Center, New York, NY
    Search for more papers by this author
  • Vincenzo Mazzaferro

    Corresponding author
    1. Hepato-Oncology Group, Surgery, Gastroenterology, Pathology, and Biostatistics, National Cancer Institute—Istituto Nazionale dei Tumori, Milan, Italy
    • Sasan Roayaie, Department of Surgery, Mount Sinai Medical Center, One Gustave L. Levy Place, Box 1259, New York, NY 10029===

      Vincenzo Mazzaferro, Department of Surgery, Istituto Nazionale Tumori, Via Venezian 1, Milan, Italy 20133===

    Search for more papers by this author
    • fax: (39)-02-2390-3259


  • Potential conflict of interest: Dr. Schwartz advises Bayer

Abstract

Asian series have shown a 5-year survival rate of ≈70% after resection of hepatocellular carcinoma (HCC) ≤2 cm. Western outcomes with resection have not been as good. In addition, ablation of HCC ≤2 cm has been shown to achieve competitive results, leaving the role of resection in these patients unclear. Records of patients undergoing resection at two Western centers between January 1990 and December 2009 were reviewed. Patients with a single HCC ≤2 cm on pathologic analysis were included. Thirty clinical variables including demographics, liver function, tumor characteristics, nature of the surgery, and the surrounding liver were examined. An exploratory statistical analysis was conducted to determine variables associated with recurrence and survival. The study included 132 patients with a median follow-up of 37.5 months. There was one (<1%) 90-day mortality. There were 32 deaths with a median survival of 74.5 months and a 5-year survival rate of 70% (63% in patients with cirrhosis). The median time to recurrence was 31.6 months and the 5-year recurrence rate was 68%. Presence of satellites (hazard ratio [HR], 2.46; P = 0.031) and platelet count <150,000/μL (HR, 2.37; P = 0.026) were independently associated with survival. Presence of satellites (HR, 2.79; P = 0.003), cirrhosis (HR, 2.3; P = 0.010), and nonanatomic resection (HR, 1.79; P = 0.031) were independently associated with recurrence. Patients with a single HCC ≤2 cm and platelet count ≥150,000/μL achieved a median survival of 138 months and a 5-year survival rate of 81%, respectively. Conclusion: Resection of HCC ≤2 cm is safe and achieves excellent results in Western centers. Recurrence continues to be a significant problem. Presence of satellites, platelet count, anatomic resection, and cirrhosis are associated with outcomes after resection, even among such early tumors. Resection should continue to be considered a primary treatment modality in patients with small HCC and well-preserved liver function. (HEPATOLOGY 2013)

Ancillary